FluGen, Inc.

24 articles about FluGen, Inc.

• New Data Published in the Journal of Infectious Diseases Demonstrate FluGen's M2SR Vaccine Candidate Substantially Enhances Mucosal & Serum Antibodies Against Drifted Influenza Strains

  11/9/2022

  FluGen, Inc. today announced the publication of new data in the Journal of Infectious Diseases showing its investigational, high dose, intranasal H3N2 M2SR influenza vaccine candidate substantially enhanced mucosal and serum antibodies against drifted H3N2 influenza viruses.

• FluGen Announces Completion of First Cohort in Age De-escalation Clinical Trial of M2SR Flu Vaccine Candidate in Pediatric Subjects Ages 6 Months to 17 Years

  9/7/2022

  FluGen, Inc., today announced the completion of enrollment of the first cohort in an age de-escalation clinical trial of M2SR (M2 Deficient Single Replication) live virus vaccine, the company's investigational supra-seasonal intranasal influenza (flu) vaccine, in volunteers ages 6 months to 17 years old.

• FluGen Announces First Subject Dosed in Phase 1b Clinical Trial of its Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults

  6/22/2022

  Study will measure immune responses generated by M2SR and high dose vaccine separately and in combination in the highly vulnerable 65-85 years old population.

• FluGen to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/5/2022

  FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced Boyd Clarke, Executive Chairman is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference.

• FluGen to Present at Baird's 2021 Global Healthcare Conference

  9/7/2021

  FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, announced management is scheduled to present at the Baird 2021 Global Healthcare Conference on Tuesday, September 14 at 5:30 PM E.T.

• FluGen Announces Publication of Positive Results from Phase 2 Human Challenge Study of Its M2SR Vaccine Candidate Against Highly Drifted Strain of H3N2 Influenza Virus

  8/2/2021

  FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, announced the publication of results from its Phase 2 human challenge study of Bris2007 M2SR, the Company's investigational, supra-seasonal, live, single-replication, intranasal influenza vaccine.

• FluGen Awarded US Department of Defense Funding to Conduct Clinical Study Evaluating Investigational M2SR Flu Vaccine and Current Standard-of-Care High Dose Vaccine

  7/1/2021

  FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, announced that it has been awarded funding from the United States Department of Defense to conduct a safety and immunogenicity study of M2SR, the Company's investigational, supra-seasonal, live, single-replication, intranasal influenza vaccine.

• FluGen Initiates NIH-Funded Trial of M2SR Flu Vaccine; First Study in Adults Up to Age 85

  5/25/2021

  Study will measure immune responses to matched and drifted virus strains in older adults, a population that is most vulnerable to mortality from flu

• 

  Biopharma Update on the Novel Coronavirus: May 7

  5/7/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 7, 2020.

• FluGen’s M2SR Influenza Vaccine Succeeds in Phase 2 Human Challenge Trial Against a Highly Mismatched Virus

  2/12/2019

  Topline data shows first flu vaccine to demonstrate protection against a multi-season mismatched H3N2 strain in a human challenge clinical trial

• FluGen Completes Dosing of Phase 2 Study to Assess Effectiveness of Novel Influenza Vaccine Designed to Protect Against Mismatched Strains

  10/15/2018

  Influenza challenge virus genetically drifted by six years from vaccine strain.

• FluGen Presents First-in-Human Phase 1a Safety and Immunogenicity Data with Novel M2SR Influenza Vaccine at ID Week

  10/4/2018

  FluGen, Inc. announced today that the company’s novel M2 deleted, single replication (M2SR) influenza vaccine was safe and well tolerated, generated a dose-response effect for both humoral and mucosal antibodies, and produced robust T-cell responses in a first-in-human phase 1a trial of 96 healthy volunteers ages 18-49 years.

• 

  Biopharma, Regulators and Researchers Turn Their Focus to Universal Flu Vaccines

  5/17/2018

  The 2017/2018 influenza season was considered one of the worst, made more so by the ineffectiveness of the season’s flu vaccine. The FDA is focusing partially on simply determining why this year’s flu vaccine missed the mark.

• FluGen Begins Enrollment of Clinical Trial of Novel Investigational Influenza Vaccine Against Multi-Season Mismatched Strains

  5/16/2018

  —Investigational vaccine designed to generate broad and durable immune protection over multiple influenza seasons —Subjects challenged with influenza virus genetically drifted by six years from vaccine strain —Study supported by U.S. Department of Defense

• FluGen Awarded $14.4 million by the Department of Defense to Test Universal Flu Vaccine Against Mismatched Strains

  10/19/2017

  FluGen Inc., announced today that it has been awarded a grant of $14.4 million through the DOD's Congressionally Directed Medical Research Programs Peer Reviewed Medical Research Program's (PRMRP) mechanism to conduct clinical challenge-studies against mismatched influenza strains with its lead universal flu vaccine, RedeeFlu.

• FluGen Announces Expanded Role For Clinical Advisory Board: Dr. Robert Belshe To Chair

  9/19/2017

• FluGen Announces C. Boyd Clarke Has Been Named Executive Chairman

  9/5/2017

• Flugen, Inc. Raises $2M More, Provides Update on Phase I Trial

  4/12/2017

• Flugen, Inc. Initiates A Phase I Clinical Trial Of The Redeeflu Universal Influenza Vaccine In Healthy Subjects

  7/27/2016

• Flugen, Inc.-Arecor Partnership Enhances Promise of Universal Flu Vaccine Through Funding Award From the UK’s Innovation Agency, the Technology Strategy Board

  7/30/2013